Sanofi India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 6:49 pm

Quick Insight

Sanofi India Ltd, operating in the pharmaceutical industry, currently trades at a price of 5,104 with a market cap of 11,755 Cr. The company exhibits a high P/E ratio of 33.0, indicating potential overvaluation, although its robust ROE and ROCE at 47.2% and 49.2% respectively reflect strong profitability and efficient capital utilization. With an OPM of 23% and a healthy net profit of 414 Cr, Sanofi India demonstrates operational efficiency. However, the lack of specific shareholder breakdown raises transparency concerns. Despite a high P/BV of 16.36x, the company's comfortable ICR of 338.20x signifies strong financial health. In conclusion, while Sanofi India shows promising financial performance, investors should closely monitor its valuation metrics and corporate governance practices for sustainable growth.

Competitors of Sanofi India Ltd

All Competitor Stocks of Sanofi India Ltd

Quarterly Result

Last Updated: August 1, 2025, 12:30 pm

Below is a detailed analysis of the quarterly data for Sanofi India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 406.00 Cr.. The value appears to be declining and may need further review. It has decreased from 536.00 Cr. (Mar 2025) to 406.00 Cr., marking a decrease of 130.00 Cr..
• For Expenses, as of Jun 2025, the value is 311.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 364.00 Cr. (Mar 2025) to 311.00 Cr., marking a decrease of 53.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 95.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 77.00 Cr..
• For OPM %, as of Jun 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 32.00% (Mar 2025) to 23.00%, marking a decrease of 9.00%.
• For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 6.00 Cr..
• For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 94.00 Cr.. The value appears to be declining and may need further review. It has decreased from 165.00 Cr. (Mar 2025) to 94.00 Cr., marking a decrease of 71.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Mar 2025) to 26.00%, marking a decrease of 2.00%.
• For Net Profit, as of Jun 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 50.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 30.22. The value appears to be declining and may need further review. It has decreased from 51.96 (Mar 2025) to 30.22, marking a decrease of 21.74.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 2:08 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: August 11, 2025, 2:43 pm

Below is a detailed analysis of the balance sheet data for Sanofi India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Equity Capital, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 23.00 Cr..
• For Reserves, as of Jun 2025, the value is 759.00 Cr.. The value appears to be declining and may need further review. It has decreased from 838.00 Cr. (Dec 2024) to 759.00 Cr., marking a decrease of 79.00 Cr..
• For Borrowings, as of Jun 2025, the value is 21.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 19.00 Cr. (Dec 2024) to 21.00 Cr., marking an increase of 2.00 Cr..
• For Other Liabilities, as of Jun 2025, the value is 436.00 Cr.. The value appears to be improving (decreasing). It has decreased from 732.00 Cr. (Dec 2024) to 436.00 Cr., marking a decrease of 296.00 Cr..
• For Total Liabilities, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..
• For Fixed Assets, as of Jun 2025, the value is 309.00 Cr.. The value appears to be declining and may need further review. It has decreased from 312.00 Cr. (Dec 2024) to 309.00 Cr., marking a decrease of 3.00 Cr..
• For CWIP, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Dec 2024) to 16.00 Cr., marking a decrease of 2.00 Cr..
• For Investments, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
• For Other Assets, as of Jun 2025, the value is 914.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,281.00 Cr. (Dec 2024) to 914.00 Cr., marking a decrease of 367.00 Cr..
• For Total Assets, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..

Notably, the Reserves (759.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Sanofi India Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
• For Diluted EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
• For Cash EPS (Rs.), as of Dec 24, the value is 195.65. This value is within the healthy range. It has decreased from 279.35 (Dec 23) to 195.65, marking a decrease of 83.70.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
• For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 875.30. It has decreased from 1,239.61 (Dec 23) to 875.30, marking a decrease of 364.31.
• For PBDIT / Share (Rs.), as of Dec 24, the value is 220.57. This value is within the healthy range. It has decreased from 377.83 (Dec 23) to 220.57, marking a decrease of 157.26.
• For PBIT / Share (Rs.), as of Dec 24, the value is 204.61. This value is within the healthy range. It has decreased from 360.61 (Dec 23) to 204.61, marking a decrease of 156.00.
• For PBT / Share (Rs.), as of Dec 24, the value is 187.57. This value is within the healthy range. It has decreased from 367.61 (Dec 23) to 187.57, marking a decrease of 180.04.
• For Net Profit / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
• For NP After MI And SOA / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
• For PBDIT Margin (%), as of Dec 24, the value is 25.19. This value is within the healthy range. It has decreased from 30.47 (Dec 23) to 25.19, marking a decrease of 5.28.
• For PBIT Margin (%), as of Dec 24, the value is 23.37. This value exceeds the healthy maximum of 20. It has decreased from 29.09 (Dec 23) to 23.37, marking a decrease of 5.72.
• For PBT Margin (%), as of Dec 24, the value is 21.42. This value is within the healthy range. It has decreased from 29.65 (Dec 23) to 21.42, marking a decrease of 8.23.
• For Net Profit Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 10. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
• For NP After MI And SOA Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 20. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
• For Return on Networth / Equity (%), as of Dec 24, the value is 48.02. This value is within the healthy range. It has decreased from 59.38 (Dec 23) to 48.02, marking a decrease of 11.36.
• For Return on Capital Employeed (%), as of Dec 24, the value is 52.72. This value is within the healthy range. It has decreased from 77.98 (Dec 23) to 52.72, marking a decrease of 25.26.
• For Return On Assets (%), as of Dec 24, the value is 25.64. This value is within the healthy range. It has decreased from 35.15 (Dec 23) to 25.64, marking a decrease of 9.51.
• For Asset Turnover Ratio (%), as of Dec 24, the value is 1.21. It has increased from 0.00 (Dec 23) to 1.21, marking an increase of 1.21.
• For Current Ratio (X), as of Dec 24, the value is 1.57. This value is within the healthy range. It has decreased from 1.92 (Dec 23) to 1.57, marking a decrease of 0.35.
• For Quick Ratio (X), as of Dec 24, the value is 0.87. This value is below the healthy minimum of 1. It has decreased from 0.89 (Dec 23) to 0.87, marking a decrease of 0.02.
• For Inventory Turnover Ratio (X), as of Dec 24, the value is 0.60. This value is below the healthy minimum of 4. It has increased from 0.00 (Dec 23) to 0.60, marking an increase of 0.60.
• For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 139.85 (Dec 23) to 0.00, marking a decrease of 139.85.
• For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 131.23 (Dec 23) to 0.00, marking a decrease of 131.23.
• For Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
• For Cash Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -31.23 (Dec 23) to 0.00, marking an increase of 31.23.
• For Interest Coverage Ratio (X), as of Dec 24, the value is 338.20. This value is within the healthy range. It has decreased from 511.18 (Dec 23) to 338.20, marking a decrease of 172.98.
• For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 235.27. This value is within the healthy range. It has decreased from 345.18 (Dec 23) to 235.27, marking a decrease of 109.91.
• For Enterprise Value (Cr.), as of Dec 24, the value is 13,783.39. It has decreased from 18,147.83 (Dec 23) to 13,783.39, marking a decrease of 4,364.44.
• For EV / Net Operating Revenue (X), as of Dec 24, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 6.37 (Dec 23) to 6.85, marking an increase of 0.48.
• For EV / EBITDA (X), as of Dec 24, the value is 27.17. This value exceeds the healthy maximum of 15. It has increased from 20.88 (Dec 23) to 27.17, marking an increase of 6.29.
• For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
• For Retention Ratios (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 30. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
• For Price / BV (X), as of Dec 24, the value is 16.36. This value exceeds the healthy maximum of 3. It has decreased from 18.28 (Dec 23) to 16.36, marking a decrease of 1.92.
• For Price / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
• For EarningsYield, as of Dec 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Dec 23) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness